PharmaCompass.com

Top Pharma Companies in 2023 by Sales [Free Excel Download at https://lnkd.in/gq_m-uhM] 1. Pfizer: $58.5 bn (⬇ 41.7%) 2. Johnson & Johnson: $54.8 bn (⬆ 4.2%) 3. AbbVie: $54.3 bn (⬇ 6.4%) 4. Merck: $53.6 bn (⬆ 3.1%) 5. Roche: $49.8 bn (⬆ 4%) Top Drugs in 2023 by Sales 1. Keytruda: $25 bn (⬆ 19.5%) 2. Eliquis: $19 bn (⬆ 3.8%) 3. Humira: $14.5 bn (⬇ 32.9%) 4. Ozempic: $13.9 bn (⬆ 59.7%) 5. Biktarvy: $11.9 bn ( ⬆ 14.1%) Read more at: https://lnkd.in/gZ3u_Ymd #PharmaFlow - Pharma Data Compilations by PharmaCompass.com #medicine #oncology #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #biotechnology #pharma #pharmacompass

#Phispers Week 51 - Weekly Pharma News Recap Sponsored by USV Peptides   - Novo Nordisk invests US$ 1.2 bn to build new rare disease drugs plant in Denmark. - Merck enters race for obesity drugs via US$ 2 bn licensing deal with Chinese biotech. - FDA okays Organon’s Vtama cream, Galderma’s Nemluvio shot for atopic dermatitis. - FDA approves Neurocrine Biosciences’ Crenessity — first med for CAH in seven decades.   #Phispers in a minute - PharmaCompass.com's Weekly News Recap   #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

#SpeakPharma – Interview with Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. With over 25 years of experience at the company, Sutton provides insights into the evolution of Quotient Sciences' Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. Anna P.. The Translational Pharmaceutics platform allows clients to remain “one step ahead of the emerging data”. How do you think this innovative approach can transform drug development? Share your thoughts in the comments below! Read the interview here: https://lnkd.in/gtP49UrG #pharmamanufacturing #pharmaceuticalindustry #pharmanews #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmaceuticals #biotechnology #pharma #pharmacompass

#Phispers Week 50 - Weekly Pharma News Recap Sponsored by Bora Pharmaceuticals   - Eli Lilly and Company to invest US$ 3 bn in Wisconsin plant to meet soaring demand for GLP-1 drugs. - GSK’s Blenrep eyes US comeback after beating J&J’s Darzalex in trial. - AbbVie’s Parkinson’s prospect from Cerevel Therapeutics buyout hits late-stage endpoints. - New trial data bolsters Johnson & Johnson-Legend Biotech’s Carvykti position among other CAR-T therapies.   #Phispers in a minute - PharmaCompass.com's Weekly News Recap   #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

November's Pharma Landscape was a Rollercoaster of Dramatic Stock Swings [Free Excel Download at https://lnkd.in/gbRue9Hu] - Vaccine makers’ stocks plummeted after RFK Jr.'s HHS nomination - Novartis, Roche, and Merck sparked a billion-dollar deals bonanza - The centerpiece of AbbVie’s US$ 8.7 bn Cerevel Therapeutics buyout failed mid-stage trials From BridgeBio's incredible comeback to Cassava Sciences' controversial Alzheimer's drug, the month had a lot! Read more at: https://lnkd.in/gUdJbXKQ #PipelineProspector Nov 2024 - Pharma & Biotech Monthly Recap by PharmaCompass.com #stockmarket #pharmastocks #pharmaceuticalindustry #pharmanews #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmaceuticals #pharma #biotech #pharmacompass

#Phispers Week 49 - Weekly Pharma News Recap Sponsored by Valsynthese - Novartis licenses PTC Therapeutics, Inc.’s Huntington’s disease program for up to US$ 2.9 bn. - Big Pharma lobbying Trump to ease Medicare price negotiations, says Reuters. - FDA okays AstraZeneca’s Imfinzi for limited stage small cell lung cancer. - Sanofi announces US$ 1 bn investment in China for new insulin production facility. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

Join Conscio's FREE Webinar on Unlocking Secrets of Biosimilar Success! 🔑 Are you looking to navigate the complex landscape of biosimilar development more efficiently? Conscio Group, in collaboration with Midas Pharma, invites you to an exclusive webinar on "Expediting Biosimilar Development: Streamlining the Path from Research to Market." Top experts reveal cutting-edge strategies on navigating regulations, common pitfalls, and successful bioassay transfer and validation. Martin Baur (Midas Pharma), Elena Guillen Benitez, MD, PhD (Leiden University Medical Center), and Klemens Weitenthaler (Conscio Group). 🕑 Date and Time: Thursday, December 12, 2:00 PM CET 👉 REGISTER NOW https://lnkd.in/e3aYGykK #biosimilars #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #biotechnology #pharma #pharmacompass

#Phispers Week 48 - Weekly Pharma News Recap Sponsored by HTL Biotechnology   - Sarepta Therapeutics’ US$ 11.4 bn mega-deal with Arrowhead Pharmaceuticals promises ‘multiple potential blockbusters’. - Novartis bets US$ 1.1 bn on Kate Therapeutics for its neuromuscular pipeline. - Roche expands CAR-T treatment arsenal with US$ 1.5 bn acquisition of Poseida Therapeutics, Inc. - After research fraud probe, Cassava’s controversial Alzheimer’s drug fails late-stage trial. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

China Takes Lead in New FDA Generic Sites, India Retains Crown [Free Excel Download at https://lnkd.in/gEuvJA4C] FDA GDUFA data shows 1,397 facilities had paid their registration fees for financial year 2025 as of Nov. 14, with Teva Pharmaceuticals, AUROBINDO PHARMA LTD, SUN PHARMA, and Dr. Reddy's Laboratories leading the way. While China is gaining momentum with new FDA registrations, India's established infrastructure and expertise in API production remain unmatched, boasting 396 FDA-registered facilities. The US follows closely behind with 328 facilities, highlighting the competitive landscape of the world’s largest generic drug market. Read more at: https://lnkd.in/g3j_cubX #PharmaFlow - Pharma Data Compilations by PharmaCompass.com #genericdrugs #manufacturing #medicine #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

#Phispers Week 47 - Weekly Pharma News Recap Sponsored by Valsynthese - Merck inks strategic deal with China’s LaNova for up to US$ 3.3 bn for cancer drug. - Vaccine makers’ stocks tumble after Trump picks RFK Jr. as health secretary. - Syndax Pharmaceuticals wins first FDA nod for new class of leukemia drugs. - FDA busts Chinese drugmaker’s attempt to hide data in warning letter. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass